ArticleCureus2025
Precision Therapeutics: A Wider Aspect of Personalized Medicines.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
"Precision medicine" will become an intrinsic part of the healthcare system in the near future, and some elaborated features are discussed in this editorial. In recent years, the rise in therapeutic disparities has created significant challenges for "one size fits all" medicines. Modern science has greater potential to deliver more personalized care in terms of medication prescription, patient treatment, health outcomes, and data storage and analysis, while remote communications are becoming regular practice in medical science. Pharmacogenetics and pharmacogenomics have emerged, reshaping precision diagnosis with broad capabilities to depict the whole biocycle in individuals. However, defining gene expression standards remains an area requiring further improvement. Additionally, understanding biological processes, improving diagnostic accuracy, considering ambient environments, optimizing therapies, ensuring standard patient care, enhancing data management, and fostering collaborations among clinicians, researchers, staff, and patients will play key roles in this new era of medicine. Personalized management of gene disorders, cancer, and infectious diseases could help avoid undue drug interactions and adverse events, thereby saving lives. Small-group trials are being conducted based on genetic traits and lifestyle factors that specify certain geographies, while large-population trials are being contextualized with outbreaks of similar pathogenic clades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.